Key facts
- This page summarizes James B. Breitmeyer's Form 4 filing for Oncternal Therapeutics, Inc..
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 15 Feb 2024, 18:00.
James B. Breitmeyer - 14 Feb 2024 Form 4 Insider Report for Oncternal Therapeutics, Inc.
- Reporting relationship
- Chief Executive Officer, Director
- Issuer ticker
- N/A
- Reported as of
- 14 Feb 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 15 Feb 2024, 18:00:26 UTC
- Prior SEC filing
- 05 Jan 2024
- Next SEC filing
- 01 May 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/Chase C. Leavitt, Attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
James B. Breitmeyer filed Form 4 for Oncternal Therapeutics, Inc. on 15 Feb 2024.
Change
- Previous filing in this sequence was filed on 05 Jan 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ONCT
transaction
Derivative
Stock Option
Award
- Transaction value
- $0
- Shares
- +28,400
- Change %
- Price
- $0.000000
- Shares after
- 28,400
- Date
- 14 Feb 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 28,400
- Exercise price
- $9.18
- Footnotes
- F1
ONCT
transaction
Derivative
Stock Option
Award
- Transaction value
- $0
- Shares
- +6,200
- Change %
- Price
- $0.000000
- Shares after
- 6,200
- Date
- 14 Feb 2024
- Ownership
- By Spouse
- Underlying class
- Common Stock
- Underlying amount
- 6,200
- Exercise price
- $9.18
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
25% of the shares subject to the stock option vest on first anniversary of the date of grant, and the remaining shares subject to the option vest in 36 equal monthly installments, subject to the recipient's continued employment or service with the Issuer on each such date.